About one in six women of reproductive age has a prescription filled at some point for a class D or X (potentially teratogenic) medication . . .
About one in six women of reproductive age has a prescription filled at some point for a class D or X (potentially teratogenic) medication, but only about half of them receive contraceptive counseling, fewer than half are filled by women using a prescription contraceptive or who are sterilized, and these women are only slightly less likely than those filling a prescription for a class A or B drug to have a documented pregnancy in the following 3 months (1.0% vs. 1.4% of prescriptions, respectively).
The findings come from a large, retrospective cohort study involving almost 500,000 female members of a large health maintenance organization in Northern California.
The authors of the study say the findings underscore the importance of contraceptive counseling, which other studies have found affects the use of contraception and the rate of unintended pregnancy. They hope the findings are also noted by policymakers in a position to influence whether contraception is covered by health insurance plans, since the cost of contraception often plays a role in whether or not it is obtained and used.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More